| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.081 | 0.06 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.06 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.06 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.058 | 0.07 |